Combination benefit of amlodipine plus atorvastatin treatment on carotid atherosclerosis in Zucker metabolic rats

Neurological Research

Volumn 35, Issue 2, 2013, Pages 181-186

  Kawai, Hiromi ^a   Kurata, Tomoko ^a   Deguchi, Kentaro ^a   Deguchi, Shoko ^a   Yamashita, Toru ^a   Ohta, Yasuyuki ^a   Omote, Yoshio ^a   Kono, Syoichiro ^a   Abe, Koji ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

Amlodipine; Atorvastatin; Common carotid artery; Zucker fatty rat

Indexed keywords

AMLODIPINE; ATORVASTATIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN P21; PROTEIN P53; SIRTUIN 1; ANTIHYPERTENSIVE AGENT; CYCLIN DEPENDENT KINASE INHIBITOR 1A; HEPTANOIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PYRROLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAROTID ATHEROSCLEROSIS; CONTROLLED STUDY; DRUG POTENTIATION; IMMUNOHISTOCHEMISTRY; MALE; METABOLIC SYNDROME X; NONHUMAN; OBESITY; RAT; ANIMAL; BIOSYNTHESIS; CAROTID ARTERY DISEASES; COMMON CAROTID ARTERY; DRUG COMBINATION; DRUG EFFECTS; ENDOTHELIUM CELL; METABOLISM;

AMLODIPINE; ANIMALS; ANTIHYPERTENSIVE AGENTS; CAROTID ARTERY DISEASES; CAROTID ARTERY, COMMON; CHEMOKINE CCL2; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DRUG THERAPY, COMBINATION; ENDOTHELIAL CELLS; HEPTANOIC ACIDS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; PYRROLES; RATS; SIRTUIN 1; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84874629244     PISSN: 01616412     EISSN: 17431328     Source Type: Journal    
DOI: 10.1179/1743132812Y.0000000131     Document Type: Article

References (47)

1. Braunersreuther V, Mach F, Steffens S. The specific role of chemokines in atherosclerosis. Thromb Haemost. 2007;97:714-721.
2. Gu L, Okada Y, Clinton SK, Gerard C, Sukhova GK, Libby P, et al. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell. 1998;2:275-281.
3. Gosling J, Slaymaker S, Gu L, Tseng S, Zlot CH, Young SG, et al. MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B. J Clin Invest. 1999;103:773-778.
4. Schecter AD, Rollins BJ, Zhang YJ, Charo IF, Fallon JT, Rossikhina M, et al. Tissue factor is induced by monocyte chemoattractant protein-1 in human aortic smooth muscle and THP-1 cells. J Biol Chem. 1997;272:28568-28573.
5. Shimano H. [Obesity and atherosclerosis]. Nihon Rinsho. 2009;67:333-337. Japanese.
6. King VL, Hatch NW, Chan HW, de Beer MC, de Beer FC, Tannock LR. A murine model of obesity with accelerated atherosclerosis. Obesity (Silver Spring). 2010;18:35-41.
7. Isomaa B, Almgren P, Tuomi T, Forsén B, Lahti K, Nissén M, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001;24:683-689.
8. Kramsch DM, Sharma RC. Limits of lipid-lowering therapy: the benefits of amlodipine as an anti-atherosclerotic agent. J Hum Hypertens. 1995;9 Suppl 1:S3-S9.
9. Thaulow E, Jorgensen B. Results and clinical implications of the CAPARES trial. The Can J Cardiol. 2000;16 Suppl D:8D-11D.
10. Lai YM, Fukuda N, Su JZ, Suzuki R, Ikeda Y, Takagi H, et al. Novel mechanisms of the antiproliferative effects of amlodipine in vascular smooth muscle cells from spontaneously hypertensive rats. Hypertens Res. 2002;25:109-115.
11. Amarenco P, Bogousslavsky J, Callahan A 3rd, Goldstein LB, Hennerici M, Rudolph AE, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Medicine. 2006;355:549-559.
12. Tsuchiya A, Nagotani S, Hayashi T, Deguchi K, Sehara Y, Yamashita T, et al. Macrophage infiltration, lectin-like oxidized-LDL receptor-1, and monocyte chemoattractant protein-1 are reduced by chronic HMG-CoA reductase inhibition. Curr Neurovasc Res. 2007;4:268-273.
13. Vaziri ND, Xu ZG, Shahkarami A, Huang KT, RodríguezIturbe B, Natarajan R. Role of AT-1 receptor in regulation of vascular MCP-1, IL-6, PAI-1, MAP kinase, and matrix expressions in obesity. Kidney Int. 2005;68:2787-2793.
14. Zucker LM. Hereditary obesity in the rat associated with hyperlipemia. Ann N Y Acad Sci. 1965;131:447-458.
15. Zucker LM, Antoniades HN. Insulin and obesity in the Zucker genetically obese rat 'fatty'. Endocrinology. 1972; 90:1320-1330.
16. Moral-Sanz J, Menendez C, Moreno L, Moreno E, Cogolludo A, Perez-Vizcaino F. Pulmonary arterial dysfunction in insulin resistant obese Zucker rats. Respir Res. 2011;12:51.
17. Contreras C, Sanchez A, Garcia-Sacristan A, Martínez MC, Andriantsitohaina R, Prieto D. Preserved insulin vasorelaxation and up-regulation of the Akt/eNOS pathway in coronary arteries from insulin resistant obese Zucker rats. Atherosclerosis. 2011;217:331-339.
18. Osmond JM, Mintz JD, Stepp DW. Preventing increased blood pressure in the obese Zucker rat improves severity of stroke. Am J Physiol. 2010;299:H55-H61.
19. Laight DW, Kengatharan KM, Gopaul NK, Anggård EE, Carrier MJ. Investigation of oxidant stress and vasodepression to glyceryl trinitrate in the obese Zucker rat in vivo. Br J Pharmacol. 1998;125:895-901.
20. Andrews TJ, Laight DW, Anggard EE, Carrier MJ. Investigation of endothelial hyperreactivity in the obese Zucker rat in-situ: reversal by vitamin E. J Pharm Pharmacol. 2000;52:83-86.
21. Subramanian R, MacLeod KM. Age-dependent changes in blood pressure and arterial reactivity in obese Zucker rats. Eur J Pharmacol. 2003;477:143-152.
22. Dorafshar AH, Moodley K, Khoe M, Lyon C, Bryer-Ash M. Pioglitazone improves superoxide dismutase mediated vascular reactivity in the obese Zucker rat. Diab Vasc Dis Res. 2010;7:20-27.
23. Ginsberg HN. Insulin resistance and cardiovascular disease. J Clin Invest. 2000;106:453-458.
24. Dandona P. Insulin resistance and endothelial dysfunction in atherosclerosis: implications and interventions. Diabetes Technol Ther. 2002;4:809-815.
25. Hsueh WA, Quinones MJ. Role of endothelial dysfunction in insulin resistance. Am J Cardiol. 2003;92:10J-7J.
26. Murthy SN, Desouza CV, Bost NW, Hilaire RC, Casey DB, Badejo AM, et al. Effects of salsalate therapy on recovery from vascular injury in female Zucker fatty rats. Diabetes 2010;59:3240-3246.
27. Mattagajasingh I, Kim CS, Naqvi A, Yamamori T, Hoffman TA, Jung SB, et al. SIRT1 promotes endothelium-dependent vascular relaxation by activating endothelial nitric oxide synthase. Proc Natl Acad Sci U S A. 2007;104:14855-14860.
28. Ota H, Akishita M, Eto M, Iijima K, Kaneki M, Ouchi Y. Sirt1 modulates premature senescence-like phenotype in human endothelial cells. J Mol Cell Cardiol. 2007;43:571-579.
29. Zhang QJ, Wang Z, Chen HZ, Zhou S, Zheng W, Liu G, et al. Endothelium-specific overexpression of class III deacetylase SIRT1 decreases atherosclerosis in apolipoprotein E-deficient mice. Cardiovasc Res. 2008;80:191-199.
30. Miyazaki R, Ichiki T, Hashimoto T, Inanaga K, Imayama I, Sadoshima J, et al. SIRT1, a longevity gene, downregulates angiotensin II type 1 receptor expression in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2008;28:1263-1269.
31. Gao P, Chen Y, Lawton MT, Barbaro NM, Yang GY, Su H, et al. Evidence of endothelial progenitor cells in the human brain and spinal cord arteriovenous malformations. Neurosurgery;67:1029-1035.
32. 2z channel dual blockers with highly potent anti-ischemic effects. Bioorgan Med Chem Lett. 1999;9:2999-3002.
33. Loke KE, Messina EJ, Mital S, Hintze TH. Impaired nitric oxide modulation of myocardial oxygen consumption in genetically cardiomyopathic hamsters. J Mol Cell Cardiol. 2000;32:2299-2306.
34. Lukic-Panin V, Kamiya T, Zhang H, Hayashi T, Tsuchiya A, Sehara Y, et al. Prevention of neuronal damage by calcium channel blockers with antioxidative effects after transient focal ischemia in rats. Brain Res. 2007;1176:143-150.
35. Rami A, Langhagen A, Steiger S. Focal cerebral ischemia induces upregulation of Beclin 1 and autophagy-like cell death. Neurobiology of disease. 2008;29:132-141.
36. Mercer J, Bennett M. The role of p53 in atherosclerosis. Cell Cycle. 2006;5:1907-1909.
37. Chang BD, Watanabe K, Broude EV, Fang J, Poole JC, Kalinichenko TV, et al. Effects of p21Waf1/Cip1/Sdi1 on cellular gene expression: implications for carcinogenesis, senescence, and age-related diseases. Proc Natl Acad Sci U S A. 2000;97:4291-4296.
38. Kunieda T, Minamino T, Nishi J, Tateno K, Oyama T, Katsuno T, et al. Angiotensin II induces premature senescence of vascular smooth muscle cells and accelerates the development of atherosclerosis via a p21-dependent pathway. Circulation. 2006;114:953-960.
39. Merched AJ, Chan L. Absence of p21Waf1/Cip1/Sdi1 modulates macrophage differentiation and inflammatory response and protects against atherosclerosis. Circulation. 2004;110: 3830-3841.
40. Nagotani S, Hayashi T, Sato K, Zhang W, Deguchi K, Nagano I, et al. Reduction of cerebral infarction in stroke-prone spontaneously hypertensive rats by statins associated with amelioration of oxidative stress. Stroke. 2005;36:670-672.
41. Hayashi T, Hamakawa K, Nagotani S, Jin G, Li F, Deguchi K, Sehara Y, et al. HMG CoA reductase inhibitors reduce ischemic brain injury of Wistar rats through decreasing oxidative stress on neurons. Brain Res. 2005;1037:52-58.
42. 2/2 mice reveals a role for chemokines in the initiation of atherosclerosis. Nature. 1998;394:894-897.
43. Libby P. Changing concepts of atherogenesis. J Intern Med. 2000;247:349-358.
44. Namiki M, Kawashima S, Yamashita T, Ozaki M, Hirase T, Ishida T, et al. Local overexpression of monocyte chemoattractant protein-1 at vessel wall induces infiltration of macrophages and formation of atherosclerotic lesion: synergism with hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2002;22:115-120.
45. Hamakawa Y, Omori N, Ouchida M, Nagase M, Sato K, Nagano I, et al. Severity dependent up-regulations of LOX-1 and MCP-1 in early sclerotic changes of common carotid arteries in spontaneously hypertensive rats. Neurol Res. 2004;26:767-773.
46. Kawai H, Deguchi S, Deguchi K, Yamashita T, Ohta Y, Shang J, et al. Synergistic benefit of combined amlodipine plus atorvastatin on neuronal damage after stroke in Zucker metabolic rat. Brain Res. 2011;1368:317-323.
47. Kawai H, Deguchi S, Deguchi K, Yamashita T, Ohta Y, Omote Y, et al. Protection against ischemic stroke damage by synergistic treatment with amlodipine plus atorvastatin in Zucker metabolic rat. Brain Res. 2011;1382:308-314.